Sugi Predict

Sugi Predict / Compounds / SCHEMBL2434129

SCHEMBL2434129

SCHEMBL2434129

O=C(O)C=Cc1cc(F)c(O)c(F)c1

nearest known ligand 0.55

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ PKM P14618 3/20 0.55
▸ PTGS1 P23219 2/20 0.55
▸ PTGS2 P35354 1/20 0.55
▸ ALOX5 P09917 3/20 0.53
▸ NFKB1 P19838 2/20 0.53
▸ STAT3 P40763 2/20 0.53
▸ NFE2L2 Q16236 2/20 0.53
▸ NFKB2 Q00653 1/20 0.53
▸ RELA Q04206 1/20 0.53
▸ KDM4E B2RXH2 5/20 0.50
▸ AKR1B10 O60218 3/20 0.50
▸ AKR1B1 P15121 3/20 0.50
▸ HSD17B10 Q99714 3/20 0.50
▸ CA12 O43570 3/20 0.50
▸ CA1 P00915 3/20 0.50
▸ CA2 P00918 3/20 0.50
▸ CA3 P07451 3/20 0.50
▸ CA4 P22748 3/20 0.50
▸ CA6 P23280 3/20 0.50
▸ CA5A P35218 3/20 0.50

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL16049121 1.00 PKM (0.55) PKMPTGS1PTGS2ALOX5NFKB1
SCHEMBL2434127 1.00 PKM (0.55) PKMPTGS1PTGS2ALOX5NFKB1
SCHEMBL584607 0.85 HCAR2 (0.50) PKMPTGS1PTGS2ALOX5NFKB1
SCHEMBL584606 0.85 HCAR2 (0.50) PKMPTGS1PTGS2ALOX5NFKB1
Hydrochloric Acid SCHEMBL27944350 0.83 HCAR2 (0.48) PKMPTGS1PTGS2ALOX5NFKB1
SCHEMBL1167211 0.83 HCAR2 (0.48) PKMPTGS1PTGS2ALOX5NFKB1
SCHEMBL1167208 0.83 HCAR2 (0.48) PKMPTGS1PTGS2ALOX5NFKB1
SCHEMBL22555964 0.83 ALOX5 (0.80) PKMPTGS1PTGS2ALOX5NFKB1
SCHEMBL514058 0.83 KDM4E (0.64) PKMPTGS1PTGS2ALOX5NFKB1
SCHEMBL514059 0.83 KDM4E (0.64) PKMPTGS1PTGS2ALOX5NFKB1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 30 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3409671-B1 ISOTHIAZOLE DERIVATIVES AS GPR120 AGONISTS FOR THE TREATMENT OF TYPE II DIABETES JANSSEN PHARMACEUTICA NV (BE) 2021-07-21 — — EP disclosed
US-10618893-B2 GPR120 agonists for the treatment of type II diabetes JANSSEN PHARMACEUTICALS NV (BE) 2020-04-14 — — US disclosed
US-20190071435-A1 GPR120 AGONISTS FOR THE TREATMENT OF TYPE II DIABETES JANSSEN PHARMACEUTICA NV (BE) 2019-03-07 — — US disclosed
EP-3409671-A1 ISOTHIAZOLE DERIVATIVES AS GPR120 AGONISTS FOR THE TREATMENT OF TYPE II DIABETES Janssen Pharmaceutica NV (BE) 2018-12-05 — — EP disclosed
US-10118922-B2 GPR120 agonists for the treatment of type II diabetes JANSSEN PHARMACEUTICA NV (BE) 2018-11-06 — — US disclosed
EP-3114123-B1 ISOTHIAZOLE DERIVATIVES AS GPR120 AGONISTS FOR THE TREATMENT OF TYPE II DIABETES JANSSEN PHARMACEUTICA NV (BE) 2018-04-25 — — EP disclosed
EP-3114123-A1 ISOTHIAZOLE DERIVATIVES AS GPR120 AGONISTS FOR THE TREATMENT OF TYPE II DIABETES Janssen Pharmaceutica NV (BE) 2017-01-11 — — EP disclosed
EP-2970161-A1 GPR120 AGONISTS FOR THE TREATMENT OF TYPE II DIABETES Janssen Pharmaceutica, N.V. (BE) 2016-01-20 — — EP disclosed
WO-2015134039-A1 ISOTHIAZOLE DERIVATIVES AS GPR120 AGONISTS FOR THE TREATMENT OF TYPE II DIABETES JANSSEN PHARMACEUTICA NV (BE) 2015-09-11 — — WO disclosed
US-9067898-B1 Isothiazole derivatives as GPR120 agonists for the treatment of type II diabetes JANSSEN PHARMACEUTICA NV (BE) 2015-06-30 — — US disclosed
EP-2367793-B1 GPR120 RECEPTOR AGONISTS AND USES THEREOF METABOLEX INC (US) 2013-03-27 — — EP disclosed
US-8309600-B2 GPR120 receptor agonists and uses thereof METABOLEX INC. (US) 2012-11-13 — — US disclosed
US-8299117-B2 GPR120 receptor agonists and uses thereof METABOLEX INC. (US) 2012-10-30 — — US disclosed
EP-2514745-A1 GPR120 receptor agonists and uses thereof Metabolex Inc. (US) 2012-10-24 — — EP disclosed
US-20110313003-A1 GPR120 RECEPTOR AGONISTS AND USES THEREOF METABOLEX, INC. 2011-12-22 — — US disclosed
WO-2011159297-A1 GPR120 RECEPTOR AGONISTS AND USES THEREOF METABOLEX, INC. (US) 2011-12-22 — — WO disclosed
EP-2367793-A1 GPR120 RECEPTOR AGONISTS AND USES THEREOF Metabolex Inc. (US) 2011-09-28 — — EP disclosed
US-20100216827-A1 ARYL GPR120 RECEPTOR AGONISTS AND USES THEREOF METABOLEX, INC. 2010-08-26 — — US disclosed
US-20100190831-A1 GPR120 RECEPTOR AGONISTS AND USES THEREOF METABOLEX, INC. 2010-07-29 — — US disclosed
WO-2010080537-A1 GPR120 RECEPTOR AGONISTS AND USES THEREOF METABOLEX, INC. (US) 2010-07-15 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20190071435-A1 GPR120 AGONISTS FOR THE TREATMENT OF TYPE II DIABETES GPR119, GLP1R, GCGR PKM 3459/4885PTGS1 727/4885PTGS2 918/4885
US-20110313003-A1 GPR120 RECEPTOR AGONISTS AND USES THEREOF GPR119, GPR52, GCGR PKM 2307/4885PTGS1 2390/4885PTGS2 1546/4885
US-20100190831-A1 GPR120 RECEPTOR AGONISTS AND USES THEREOF GPR119, GPR52, GCGR PKM 2307/4885PTGS1 2390/4885PTGS2 1546/4885
US-10118922-B2 GPR120 agonists for the treatment of type II diabetes GPR119, GLP1R, GCGR PKM 3459/4885PTGS1 727/4885PTGS2 918/4885
US-10618893-B2 GPR120 agonists for the treatment of type II diabetes GPR119, GLP1R, GCGR PKM 3459/4885PTGS1 727/4885PTGS2 918/4885
US-20100216827-A1 ARYL GPR120 RECEPTOR AGONISTS AND USES THEREOF GPR119, GPR52, GCGR PKM 2732/4885PTGS1 2446/4885PTGS2 1677/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.